JP6475167B2 - ジスルフィド結合した多価ｍｈｃクラスｉを含む多機能タンパク質 - Google Patents

ジスルフィド結合した多価ｍｈｃクラスｉを含む多機能タンパク質 Download PDF

Info

Publication number
JP6475167B2
JP6475167B2 JP2015548483A JP2015548483A JP6475167B2 JP 6475167 B2 JP6475167 B2 JP 6475167B2 JP 2015548483 A JP2015548483 A JP 2015548483A JP 2015548483 A JP2015548483 A JP 2015548483A JP 6475167 B2 JP6475167 B2 JP 6475167B2
Authority
JP
Japan
Prior art keywords
seq
disulfide
antibody
antigen
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015548483A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501900A (ja
JP2016501900A5 (OSRAM
Inventor
ガイ ゲオルゲス
ガイ ゲオルゲス
サビーネ イムホフ−ユング
サビーネ イムホフ−ユング
ヘンドリック クノエゲン
ヘンドリック クノエゲン
マルティナ シュミットネゲル
マルティナ シュミットネゲル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2016501900A publication Critical patent/JP2016501900A/ja
Publication of JP2016501900A5 publication Critical patent/JP2016501900A5/ja
Application granted granted Critical
Publication of JP6475167B2 publication Critical patent/JP6475167B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2015548483A 2012-12-21 2013-12-18 ジスルフィド結合した多価ｍｈｃクラスｉを含む多機能タンパク質 Expired - Fee Related JP6475167B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12198904 2012-12-21
EP12198904.0 2012-12-21
EP13175469.9 2013-07-08
EP13175469 2013-07-08
PCT/EP2013/077109 WO2014096015A1 (en) 2012-12-21 2013-12-18 Disulfide-linked multivalent mhc class i comprising multi-function proteins

Publications (3)

Publication Number Publication Date
JP2016501900A JP2016501900A (ja) 2016-01-21
JP2016501900A5 JP2016501900A5 (OSRAM) 2018-03-08
JP6475167B2 true JP6475167B2 (ja) 2019-02-27

Family

ID=49779923

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015548483A Expired - Fee Related JP6475167B2 (ja) 2012-12-21 2013-12-18 ジスルフィド結合した多価ｍｈｃクラスｉを含む多機能タンパク質

Country Status (16)

Country Link
US (1) US10501521B2 (OSRAM)
EP (1) EP2935328B1 (OSRAM)
JP (1) JP6475167B2 (OSRAM)
KR (1) KR20150097688A (OSRAM)
CN (1) CN104884474A (OSRAM)
AR (1) AR094149A1 (OSRAM)
AU (1) AU2013360775B2 (OSRAM)
CA (1) CA2889788A1 (OSRAM)
ES (1) ES2700984T3 (OSRAM)
HK (1) HK1214276A1 (OSRAM)
IL (1) IL238499B (OSRAM)
MX (1) MX361076B (OSRAM)
PL (1) PL2935328T3 (OSRAM)
RU (1) RU2015129640A (OSRAM)
SG (1) SG11201504414UA (OSRAM)
WO (1) WO2014096015A1 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
WO2014083004A1 (en) * 2012-11-30 2014-06-05 Roche Glycart Ag Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins
RU2015129640A (ru) 2012-12-21 2017-01-26 Ф.Хоффманн-Ля Рош Аг Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1
EP3065771B1 (en) 2013-11-04 2019-03-20 UTI Limited Partnership Methods and compositions for sustained immunotherapy
CN107249641B (zh) * 2015-02-18 2021-07-09 豪夫迈·罗氏有限公司 用于特异性诱导针对靶细胞的t细胞细胞毒性的免疫缀合物
CN107847582A (zh) 2015-05-06 2018-03-27 优迪有限合伙公司 用于持续疗法的纳米颗粒组合物
CA3019005A1 (en) 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CA3042615A1 (en) * 2016-11-09 2018-05-17 Uti Limited Partnership Recombinant pmhc class ii molecules
JP7250677B2 (ja) 2016-12-22 2023-04-03 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR102619015B1 (ko) 2017-03-15 2023-12-28 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
AU2018374569B2 (en) 2017-11-29 2024-10-17 Uti Limited Partnership Methods of treating autoimmune disease
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
JP7580754B2 (ja) * 2018-06-20 2024-11-12 ダンマークス テクニスク ユニバーシテット 免疫細胞操作用の安定化されたｍｈｃ分子を有するスカフォールド
WO2020056152A1 (en) * 2018-09-12 2020-03-19 Chang Liu Single chain constructs
DE102018122546B3 (de) * 2018-09-14 2019-12-05 Immatics Biotechnologies Gmbh Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden
JP7677892B2 (ja) * 2018-12-28 2025-05-15 エフ． ホフマン－ラ ロシュ アーゲー 免疫応答が増幅された患者における治療的使用のためのペプチド－ｍｈｃ－ｉ－抗体融合タンパク質
US11346844B2 (en) 2019-04-26 2022-05-31 Protein Metrics Inc. Intact mass reconstruction from peptide level data and facilitated comparison with experimental intact observation
WO2020243315A1 (en) * 2019-05-29 2020-12-03 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
JP2023509793A (ja) * 2020-01-10 2023-03-09 ダイン セラピューティクス，インコーポレーテッド 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用
WO2021168388A1 (en) * 2020-02-21 2021-08-26 3T Biosciences, Inc. Yeast display libraries, associated compositions, and associated methods of use
CA3169949A1 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP4182465A4 (en) * 2020-07-14 2024-08-07 Cue Biopharma, Inc. T-CELL MODULATORY POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
KR20230141817A (ko) * 2021-02-07 2023-10-10 치아타이 티안큉 파마수티컬 그룹 주식회사 이중특이 항체
WO2023023641A2 (en) * 2021-08-20 2023-02-23 3T Biosciences, Inc. Peptide-hla-b*35 libraries, associated compositions, and associated methods of use
CN115838432B (zh) * 2022-07-08 2023-12-08 浙江大学 一种靶向调控抗原特异性t细胞的融合蛋白及应用
WO2025113640A1 (zh) * 2023-11-30 2025-06-05 南京维立志博生物科技股份有限公司 结合lilrb1/2或pd1-lilrb1/2的抗体及其用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
DE3825615A1 (de) 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
US5068088A (en) 1988-11-03 1991-11-26 Igen, Inc. Method and apparatus for conducting electrochemiluminescent measurements
KR0143993B1 (ko) 1988-11-03 1998-07-15 리차아드 제이 매씨이 전기화학 발광성 분석
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
JPH03240498A (ja) 1990-02-16 1991-10-25 Nobuyoshi Shimizu 抗体およびそれを使用した免疫分析方法
IL100866A (en) 1991-02-06 1995-10-31 Igen Inc Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
US6361964B1 (en) * 1997-08-12 2002-03-26 Massachusetts Institute Of Technology Eukaryotic disulfide bond-forming proteins and related molecules and methods
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
PT1068241E (pt) 1998-04-02 2007-11-19 Genentech Inc Variantes de anticorpos e respectivos fragmentos
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US20030175884A1 (en) 2001-08-03 2003-09-18 Pablo Umana Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US7521197B2 (en) 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
WO1999064597A1 (en) 1998-06-10 1999-12-16 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services β2 MICROGLOBULIN FUSION PROTEINS AND HIGH AFFINITY VARIANTS
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU3672800A (en) 1999-04-09 2000-11-14 Kyowa Hakko Kogyo Co. Ltd. Method for controlling the activity of immunologically functional molecule
DE60022369T2 (de) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP1274852A2 (en) 2000-04-12 2003-01-15 University Of Rochester Targeted vaccine delivery systems
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
HU231090B1 (hu) 2000-10-06 2020-07-28 Kyowa Kirin Co., Ltd. Antitest-kompozíciót termelő sejt
GB0103998D0 (en) 2001-02-19 2001-04-04 King S College London Method
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003084569A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
JP4832719B2 (ja) 2002-04-09 2011-12-07 協和発酵キリン株式会社 ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬
EP1498485A4 (en) 2002-04-09 2006-09-06 Kyowa Hakko Kogyo Kk MODIFIED GENOME CELLS
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR ENHANCING ACTIVITY OF BINDING ANTIBODY COMPOSITION WITH FC GAMMA IIIA RECEPTOR
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US20030199024A1 (en) 2002-04-19 2003-10-23 Hansen Ted H. Single chain trimers of class I MHC molecules
US8895020B2 (en) 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CN103833854B (zh) 2002-12-16 2017-12-12 健泰科生物技术公司 免疫球蛋白变体及其用途
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JP4473257B2 (ja) 2003-04-02 2010-06-02 エフ．ホフマン−ラ ロシュ アーゲー インスリン様成長因子ｉ受容体に対する抗体及びその使用
WO2005099361A2 (en) * 2003-07-10 2005-10-27 Vaccinex, Inc. MHC CLASS I - PEPTIDE-ANTIBODY CONJUGATES WITH MODIFIED β2-MICROGLOBULIN
CA2542046A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
EP1705251A4 (en) 2003-10-09 2009-10-28 Kyowa Hakko Kirin Co Ltd PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE
BRPI0416262B1 (pt) 2003-11-05 2022-04-12 Roche Glycart Ag Anticorpo anti-cd20 humano tipo ii humanizado, seu método de produção, seus usos, bem como polinucleotídeo isolado, vetor de expressão e composição farmacêutica
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2007025554A1 (en) 2005-08-29 2007-03-08 Medizinische Hochschule Hannover Method for the generation of antigen-specific t-cells and uses thereof
US20080014203A1 (en) 2006-04-11 2008-01-17 Silke Hansen Antibodies against insulin-like growth factor I receptor and uses thereof
WO2007136778A2 (en) 2006-05-19 2007-11-29 Teva Pharmaceutical Industries, Ltd. Fusion proteins, uses thereof and processes for producing same
US20080138354A1 (en) * 2006-07-21 2008-06-12 City Of Hope Cytomegalovirus vaccine
US8992937B2 (en) 2006-08-28 2015-03-31 Washington University Disulfide trap MHC class I molecules and uses therefor
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US10611818B2 (en) * 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
RU2379055C1 (ru) 2008-04-30 2010-01-20 Виктор Владимирович Кешелава Способ лечения онкологических заболеваний
ES2694564T3 (es) 2011-02-10 2018-12-21 Roche Glycart Ag Polipéptidos de interleucina-2 mutantes
BR112013029746B1 (pt) * 2011-06-22 2021-02-02 F. Hoffmann-La Roche Ag método para a produção recombinante de um complexo, complexo, formulação farmacêutica e uso do complexo
RU2015129640A (ru) 2012-12-21 2017-01-26 Ф.Хоффманн-Ля Рош Аг Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1
CN107847582A (zh) 2015-05-06 2018-03-27 优迪有限合伙公司 用于持续疗法的纳米颗粒组合物

Also Published As

Publication number Publication date
IL238499A0 (en) 2015-06-30
EP2935328B1 (en) 2018-10-10
MX2015007239A (es) 2015-08-12
JP2016501900A (ja) 2016-01-21
US10501521B2 (en) 2019-12-10
WO2014096015A1 (en) 2014-06-26
KR20150097688A (ko) 2015-08-26
MX361076B (es) 2018-11-27
RU2015129640A (ru) 2017-01-26
EP2935328A1 (en) 2015-10-28
IL238499B (en) 2018-10-31
CA2889788A1 (en) 2014-06-26
HK1214276A1 (zh) 2016-07-22
AU2013360775A1 (en) 2015-05-14
US20150344586A1 (en) 2015-12-03
SG11201504414UA (en) 2015-07-30
CN104884474A (zh) 2015-09-02
PL2935328T3 (pl) 2019-02-28
AR094149A1 (es) 2015-07-15
ES2700984T3 (es) 2019-02-20
AU2013360775B2 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
JP6475167B2 (ja) ジスルフィド結合した多価ｍｈｃクラスｉを含む多機能タンパク質
JP6542303B2 (ja) 複合体を含むｍｈｃクラスｉを用いてウイルス特異的細胞傷害性ｔ細胞を循環させることによる標的細胞の除去
EP2925780B1 (en) Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins
NZ617348B2 (en) Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes
HK40013032A (en) Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes
HK1191349A (en) Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180125

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20180125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180919

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190131

R150 Certificate of patent or registration of utility model

Ref document number: 6475167

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees